Skip to main content
Contact Us
Subscribe
E-Edition
44°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Crinetics Pharmaceuticals, Inc.
< Previous
1
2
Next >
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
December 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
November 15, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
November 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
November 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
October 16, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
October 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
October 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
September 26, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
August 29, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
June 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
May 30, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
May 22, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 19, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.